The Impact of Arthritis Medications During Pregnancy on Maternal and Neonatal Health Outcomes

Project number: 
13-084
Approval date: 
Tuesday, March 18, 2014
Principal Investigator: 
De Vera,Mary
Institution: 
University of British Columbia (UBC)
Funding Agency: 
The Arthritis Society
Datasets requested: 
Consolidation - demographic (Ministry of Health)
PharmaNet
Hospital Separations (BC Ministry of Health)
Consolidation registry (Ministry of Health)
Perinatal Services BC
Stillbirths (BC Vital Statistics Agency)
consolidation - census geocodes
Births (BC Vital Statistics Agency)
Deaths (BC Vital Statistics Agency)
Medical Services Plan (BC Ministry of Health)
Research objective: 

Objective 1: Describe perinatal use of arthritis medications by: a) quantifying prevalence of use of arthritis medications; and b) describing patterns of use in the year before, during, and the year after pregnancy. As this is a descriptive objective, we will not formally test hypotheses.

Research Question 1: What is the prevalence and pattern of arthritis medication use before, during, and after pregnancy among women with arthritis.

Objective 2: Assess maternal outcomes associated with perinatal use of arthritis medications by quantifying the magnitude of the risk of: a) spontaneous abortions and b) caesarean deliveries to test hypothesis that arthritis medications impact health outcomes of the mother.

Research Question(s) 2: Do arthritis medications increase the risk of spontaneous abortions? Do arthritis medications increase the risk of caesarean deliveires?

Objective 3: Assess neonatal outcomes associated with perinatal use of arthritis medications by quantifying the magnitude of the risk of: a) major congenital malformations and b) small for gestational age to test hypothesis that arthritis medications impact health outcomes of the child.

Research Question(s) 3: Do arthritis medications increase the risk of having infants with major congenital malformations? Do arthritis medications increase the risk having infants who are small-for-gestational-age?

Publications: 

Presentation of research material (poster/seminar/lecture etc.)

  • Tsao NW, Lynd LD, Marra CA, Sayer E, De Vera MA. Patterns of Biologics Use among Women with Autoimmune Disease Before, During, and After Pregnancy: A Population-based Study. Poster presentation. Canadian Rheumatology Association Conference. February 2016
  • Tsao NW. Patterns of Biologics Use among Women with Autoimmune Disease Before, During, and After Pregnancy: A Population-based Study. Oral presentation. Arthritis Research Canada - University of California San Francisco Joint Research Day. February 2016
  • De Vera MA, Sayre EC, Tsao NW, Avina-Zubieta JA. Perinatal patterns of medication use in women with rheumatoid arthritis: A population-based study. Poster presentation. American College of Rheumatology Annual Meeting. September 2015

Conference abstract/presentation

  • Conference Presentation
    Tsao NW, Lynd LD, Sadatsafavi M, Li K, Sayre E, De Vera M. Discontinuation of Biologic Drugs 1-year Before Pregnancy and During Pregnancy: A Real-World Comparison between Inflammatory Bowel Disease and Rheumatoid Arthritis. Canadian Rheumatology Association Conference (Ottawa, ON) February 2017

Page last revised: December 5, 2017